These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
780 related articles for article (PubMed ID: 25799566)
41. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis. Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487 [TBL] [Abstract][Full Text] [Related]
42. Radiation dose escalation for locally advanced nasopharyngeal carcinoma patients with local and/or regional residual lesions after standard chemoradiotherapy: a non-randomized, observational study. Jin T; Liu NF; Jin QF; Hua YH; Chen XZ Radiat Oncol; 2022 Nov; 17(1):176. PubMed ID: 36345003 [TBL] [Abstract][Full Text] [Related]
43. Concurrent chemoradiotherapy with additional chemotherapy for nasopharyngeal carcinoma: A pooled analysis of propensity score-matching studies. Li M; Zhang B; Chen Q; Zhang L; Mo X; Chen Z; Jin Z; Chen L; You J; Zhang S Head Neck; 2021 Jun; 43(6):1912-1927. PubMed ID: 33644916 [TBL] [Abstract][Full Text] [Related]
44. Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era. Zhang LN; Gao YH; Lan XW; Tang J; Su Z; Ma J; Deng W; OuYang PY; Xie FY Oncotarget; 2015 Dec; 6(41):44019-29. PubMed ID: 26528755 [TBL] [Abstract][Full Text] [Related]
45. Significant survival benefit of adjuvant chemotherapy after concurrent chemoradiotherapy in locally advanced high-risk nasopharyngeal carcinoma. Liang ZG; Chen XQ; Lin GX; Yu BB; Chen KH; Zhong QL; Nong SK; Li L; Qu S; Su F; Zhao W; Li Y; Zhu XD Sci Rep; 2017 Feb; 7():41449. PubMed ID: 28150694 [TBL] [Abstract][Full Text] [Related]
46. Induction chemotherapy followed by intensity-modulated radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma: A retrospective analysis. He Y; Zhao Z; Wang Y; He J; Chai J; Wei Z; Guan H; Wang J; Liu Z; Li R; Mu X; He L; Peng X Clin Otolaryngol; 2021 Sep; 46(5):976-982. PubMed ID: 33821552 [TBL] [Abstract][Full Text] [Related]
47. Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis. Tang SQ; Xu C; Wang XS; Tang LL; Li WF; Chen L; Mao YP; Guo R; Liu Q; Sun Y; Ma J Oral Oncol; 2020 Jun; 105():104686. PubMed ID: 32283514 [TBL] [Abstract][Full Text] [Related]
48. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J Lancet Oncol; 2012 Feb; 13(2):163-71. PubMed ID: 22154591 [TBL] [Abstract][Full Text] [Related]
49. Comparison of concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by radiation in patients with advanced nasopharyngeal carcinoma in endemic area: experience of 128 consecutive cases with 5 year follow-up. Wu SY; Wu YH; Yang MW; Hsueh WT; Hsiao JR; Tsai ST; Chang KY; Chang JS; Yen CJ BMC Cancer; 2014 Oct; 14():787. PubMed ID: 25351202 [TBL] [Abstract][Full Text] [Related]
50. Individualized Concurrent Chemotherapy for Patients with Stage III-IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy. Ji P; Lu Q; Chen X; Chen Y; Peng X; Chen Z; Lin C; Lin S; Zong J Cancer Res Treat; 2023 Oct; 55(4):1113-1122. PubMed ID: 37170497 [TBL] [Abstract][Full Text] [Related]
51. A phase III randomized study comparing neoadjuvant chemotherapy with concurrent chemotherapy combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma: updated long-term survival outcomes. Xu T; Zhu G; He X; Ying H; Hu C Oral Oncol; 2014 Feb; 50(2):71-6. PubMed ID: 24315404 [TBL] [Abstract][Full Text] [Related]
52. Chemoradiotherapy with weekly low-dose docetaxel and cisplatin concurrent with radiation for patients with locally advanced nasopharyngeal carcinoma, followed by adjuvant chemotherapy for selected patients. Nakahara S; Hanamoto A; Seo Y; Miyaguchi S; Yamamoto Y; Tomiyama Y; Yoshii T; Takenaka Y; Yoshioka Y; Isohashi F; Ogawa K; Inohara H Jpn J Clin Oncol; 2016 Oct; 46(10):903-910. PubMed ID: 27474126 [TBL] [Abstract][Full Text] [Related]
53. Long-Term Results of Concurrent Chemoradiotherapy for Advanced N2-3 Stage Nasopharyngeal Carcinoma. Yin L; Bian XH; Wang X; Chen M; Wu J; Xu JH; Qian PD; Guo WJ; Jiang XS; Zhu HF; Gu JJ; Wu JF; Zhang YW; He X PLoS One; 2015; 10(9):e0137383. PubMed ID: 26367317 [TBL] [Abstract][Full Text] [Related]
54. Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma: A 5-Year Follow-up Secondary Analysis of a Randomized Clinical Trial. Tang QN; Liu LT; Qi B; Guo SS; Luo DH; Sun R; Sun XS; Chen DP; Guo L; Mo HY; Wang P; Liu SL; Liang YJ; Li XY; Yang ZC; Chen QY; Mai HQ; Tang LQ JAMA Netw Open; 2021 Dec; 4(12):e2138470. PubMed ID: 34928359 [TBL] [Abstract][Full Text] [Related]
55. Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma. Wang K; Dong J; He S; Wang X; Jiang C; Hu P; Guo J; Cai X; Wang X BMC Cancer; 2019 May; 19(1):482. PubMed ID: 31117967 [TBL] [Abstract][Full Text] [Related]
56. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up. You R; Hua YJ; Liu YP; Yang Q; Zhang YN; Li JB; Li CF; Zou X; Yu T; Cao JY; Zhang MX; Jiang R; Sun R; Mo HY; Guo L; Cao KJ; Lin AH; Sun Y; Qian CN; Ma J; Chen MY Theranostics; 2017; 7(8):2314-2324. PubMed ID: 28740554 [TBL] [Abstract][Full Text] [Related]
57. Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma. Wang C; Tang X; Wang J; Song J; Xu Y Otolaryngol Head Neck Surg; 2017 Aug; 157(2):233-238. PubMed ID: 28418781 [TBL] [Abstract][Full Text] [Related]
58. Association of Chemoradiotherapy Regimens and Survival Among Patients With Nasopharyngeal Carcinoma: A Systematic Review and Meta-analysis. Zhang B; Li MM; Chen WH; Zhao JF; Chen WQ; Dong YH; Gong X; Chen QY; Zhang L; Mo XK; Luo XN; Tian J; Zhang SX JAMA Netw Open; 2019 Oct; 2(10):e1913619. PubMed ID: 31626318 [TBL] [Abstract][Full Text] [Related]
59. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study. Liu DH; Zhou XY; Pan YG; Chen S; Ye ZH; Chen GD Cancer Med; 2020 Feb; 9(4):1287-1297. PubMed ID: 31859464 [TBL] [Abstract][Full Text] [Related]
60. T1-2N1M0 nasopharyngeal carcinoma chemotherapy or not: A retrospective study. Li PJ; Chen M; Tian Y PLoS One; 2023; 18(3):e0279252. PubMed ID: 36862672 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]